Association of adverse events and quality of life in patients with unresectable hepatocellular carcinoma.

ABSTRACT:

Purpose

Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related deaths globally. Patients are often diagnosed with advanced disease, in which systemic and locoregional therapies are commonly used as first-line treatment. Such treatments can cause adverse events (AEs) that negatively affect quality of life (QoL), which is particularly undesirable where prognosis is poor. The aim of the present study was to evaluate the impact of common AEs on QoL in patients with HCC.

Methods

Data from the SARAH randomized controlled trial (RCT) were analyzed. Given the large number of distinct AEs that occurred in the trial, AEs were grouped as in the SARAH trial and prioritized using principal component analysis (PCA). Linear mixed-effects models were then applied with a

SUBMITTER: Agirrezabal I 

PROVIDER: S-EPMC11599365 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature